SAB Biotherapeutics Inc (SABS) - Total Assets
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) holds total assets worth $183.45 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SAB Biotherapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
SAB Biotherapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how SAB Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data.
SAB Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
SAB Biotherapeutics Inc's total assets of $183.45 Million consist of 53.8% current assets and 46.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.1% |
| Accounts Receivable | $54.95K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how SAB Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SABS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SAB Biotherapeutics Inc's current assets represent 53.8% of total assets in 2024, an increase from 51.6% in 2019.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2024, down from 35.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
SAB Biotherapeutics Inc Competitors by Total Assets
Key competitors of SAB Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
SAB Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.50 | 3.69 | 3.11 |
| Quick Ratio | 10.50 | 3.69 | 3.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $102.48 Million | $23.72 Million | $23.39 Million |
SAB Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between SAB Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.12 |
| Latest Market Cap to Assets Ratio | 3.74 |
| Asset Growth Rate (YoY) | -47.3% |
| Total Assets | $44.20 Million |
| Market Capitalization | $165.20 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values SAB Biotherapeutics Inc's assets at a significant premium (3.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: SAB Biotherapeutics Inc's assets decreased by 47.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SAB Biotherapeutics Inc (2019–2024)
The table below shows the annual total assets of SAB Biotherapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $44.20 Million | -47.35% |
| 2023-12-31 | $83.94 Million | +64.90% |
| 2022-12-31 | $50.90 Million | -37.26% |
| 2021-12-31 | $81.14 Million | +43.52% |
| 2020-12-31 | $56.54 Million | +214.04% |
| 2019-12-31 | $18.00 Million | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune… Read more